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Abstract
Changes in metacarpal cortical bone mineral density (BMD) using
digital x-ray radiogrammetry were studied in patients with early
rheumatoid arthritis. After 1, 2, and 5 years, large BMD losses were
found: –1.7%, –2.8%, and –5.6%, respectively. Elevated erythro-
cyte sedimentation rate and anti-cyclic citrullinated peptide levels
were independent predictors of bone loss, indicating that the
largest amount of bone loss was found in patients with severe
inflammation and high production of auto-antibodies, who are
known to be at the highest risk of developing radiological bone
damage. Studies are needed about the spatial and time relationship
between erosions and juxta-articular and metacarpal bone loss.
The elegant study by Bøyesen and colleagues [1] in the
previous issue of Arthritis Research & Therapy, in which they
observed the changes in hand bone mineral density (BMD)
using digital x-ray radiogrammetry (DXR) in 163 patients with
early rheumatoid arthritis (RA), is most welcome. DXR
measures the cortical thickness, width, and porosity of the
central parts of metacarpals 2 to 4. After 1, 2, and 5 years of
observation, the decreases in hand BMD were –1.7%,
–2.8%, and –5.6%, respectively. Elevated levels of both
erythrocyte sedimentation rate (ESR) and anti-cyclic citrulli-
nated peptide (anti-CCP) were independent predictors of
hand bone loss at all time points, indicating that the largest
amounts of bone loss were found in patients with severe
inflammation and high levels of auto-antibodies; from earlier
data, we know that these patients are prone to develop
severe RA with radiological joint damage [2].
RA is a chronic progressive disorder characterised by syno-
vitis, bone and cartilage degradation of the joints, and extra-
articular symptoms. Based on the dramatic improvement in
treatment options in RA, clinical remission is a realistic target
of therapy [2]. In particular, the use of biologicals early in the
course of RA is exciting and addresses two of the most
important research questions in modern rheumatology: is it
possible to predict which RA patients will have a favourable
response to conventional (methotrexate, or MTX) therapy?
And what are the characteristics of RA patients with an
unfavourable prognosis, estimated by radiological joint
damage, for which more aggressive therapy is indicated?
Thus, there is an urgent need to develop validated assess-
ment tools for identifying patients who are at risk for a poor
prognosis, estimated by early radiological joint damage. Juxta-
articular bone loss and subchondral bone oedema due to the
replacement of marrow fat by heavily vascularised
inflammatory cells are the earliest signs of bone involvement
in RA and may even precede the development of
radiologically detectable erosions of the joint [3,4].
In the Norwegian study, changes in hip and spine BMD were
not mentioned, but in the BeST (Behandel Strategieën) study
(also in patients with early RA), it was observed that the hand
bone loss was roughly two to five times higher than the
generalised bone loss at the spine and hips [5]. This
difference presumably reflects the fact that BMD changes at
the hands are more sensitive to cytokine stimulation in the
adjacent inflamed joints. Güler-Yüksel and colleagues [5]
observed that the changes in hand BMD mirror the
progression of radiological joint damage according to the
Sharp-van der Heijde score (SHS). This inverse relationship
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suggests that adjacent joint damage and cortical metacarpal
bone loss presumably result from the same mechanisms:
inflammation-driven upregulation of tumour necrosis factor-
alpha, interleukin-1 (IL-1), IL-6, and receptor activator of
nuclear factor-kappa B ligand (RANKL), leading to stimulation
of osteoclastic bone resorption, in combination with inhibited
osteoblastic bone formation, at least partly related to the
upregulation of dickkopf-1 [6]. If indeed the mechanisms are
similar, does aggressive antirheumatic therapy protect
against both local joint damage and cortical metacarpal bone
loss? The answer is yes, as shown for combination therapy of
MTX with adalimumab, for combination therapy with MTX and
prednisone or infliximab, and for denosumab [7-9].
One limitation of the study is the lack of data on clinical joint
inflammation and radiographic joint damage (SHS) for deter-
mining the correlation in space and time with cortical meta-
carpal bone loss. Indeed, periarticular trabecular bone loss,
cortical bone loss (which is most pronounced at the endo-
cortical site), and subchondral bone oedema are probably the
first detectable signs of subchondral inflammation. This could
be explained by direct communication between the joints and
bone marrow by upregulated local blood flow or by the
presence of radiologically still-undetectable small erosions or
by both [2,3]. Unfortunately, DXR does not allow us to
specify the degree to which bone loss occurs at the
endocortical bone site and at the periosteal site. The tight
relationship between SHS and hand bone loss has another
consequence: it could be argued that the SHS at baseline is
missing in the Norwegian prediction model. Another limitation
is the lack of data on bone markers, such as the RANKL/
osteoprotegerin ratio and bone and cartilage markers (CTX-1
and -2), which independently predict radiographic joint
damage in RA [10,11].
The main disadvantage of the SHS is that it is a time-
consuming and difficult scoring method, usually performed
only in clinical trials. The use of hand DXR is potentially
attractive since the measurements can be performed with
standard x-rays of the hands and because of the early finding
of local hand bone loss. On the other hand, the devices to
measure the metacarpals are not widely available, and
sending the digital radiographs to a central laboratory may be
costly. Second, a crucial question remains: what is the
clinical relevance of measuring local hand bone density?
However, the results of the Norwegian study should incite
researchers to further analyse the sequence of juxta-articular
bone events (bone oedema and periarticular trabecular and
cortical bone loss and erosions) in early RA.
In summary, the observation that elevated levels of both ESR
and anti-CCP are predictors of hand bone loss measured by
DXR seems to be adequate and important. Nevertheless,
more data and clinical experience are needed before the use
of hand DXR can be successfully introduced in daily practice.
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